

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 237/32, 401/04, 401/06 C07D 403/04, 403/06, 403/10 C07D 409/04, 409/06, 413/04 C07D 413/06, 413/10, 417/04 C07D 417/06, A61K 31/50 A61K 31/535, 31/54</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/10151</p> <p>(43) International Publication Date: 11 May 1994 (11.05.94)</p>
<p>(21) International Application Number: PCT/US93/10386</p> <p>(22) International Filing Date: 28 October 1993 (28.10.93)</p> <p>(30) Priority data: 970,358 2 November 1992 (02.11.92) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 970,358 (CON) Filed on 2 November 1992 (02.11.92)</p> <p>(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</p>		<p>(72) Inventors; and (75) Inventors/Applicants (for US only) : CHAKRAVARTY, Prasun, K. [IN/US]; 16 Churchill Road, Edison, NJ 08820 (US). NAYLOR, Elisabeth, M. [GB/US]; 2219 North Avenue #7, Scotch Plains, NJ 07076 (US). CHEN, Anna [US/US]; 852 Madison Avenue, Rahway, NJ 07065 (US).</p> <p>(74) Agent: CAMARA, Valerie, J.; Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</p> <p>(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>

(54) Title: SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS



(57) Abstract

Novel substituted phthalazinones of formula (I) are useful as neurotensin antagonists.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


- 1 -

5
TITLE OF THE INVENTION

SUBSTITUTED PHTHALAZINONES AS NEUROTENSIN
ANTAGONISTS

10
INTRODUCTION OF THE INVENTION

This invention relates to novel substituted phthalazinone
compounds represented by formula I:



which are antagonists of peptide hormone neurotensin. The invention is
also concerned with the use of aforementioned neurotensin antagonists
in the treatment of states mediated by neurotensin.

- 2 -

BACKGROUND OF THE INVENTION

Neurotensin (NT) is a tridecapeptide hormone (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH), originally isolated from the bovine hypothalamus [Carraway, R. and Leeman, S. E., J. Biol. Chem., **248**, 6854 (1973)], has subsequently been shown to be distributed in the brain [Uhl, G. R., et al., Proc. Natl. Acad. Sci. USA, **74**, 4059-4063 (1977)], gastrointestinal tract [1]. Kitabgi, P., Carraway, R. and Leeman, S. E., J. Biol. Chem., **251**, 7053 (1976); 2). Carraway, R., Kitabgi, P., and Leeman, S. E., J. Biol. Chem., **253**, 7996 (1978); 3). Helmstadler, V., Taugner, C., Feurle, G. E. and Frossman, W. G., Histochemistry, **53**, 35-41 (1977)] and pancreas [Feurle, G. E. and Niestroj, S., Pancreas, **6**, 202-207 (1991) and references cited therein] of various animals including human [Mai, J. K., et al., Neuroscience, **22**, 499-524 (1987)]. Although the physiological role of neurotensin has not yet been clearly understood, this endogenous peptide participates in a wide spectrum of central [1]. Prange, A. J. and Nemeroff, C. B., Annal. NY Acad. Sciences, **400**, 368-375 (1982); 2). Stowe, Z. N. and Nemeroff, C. B., Life Sci., **49**, 987-1002, (1991); 3) Kitabgi, P., Neurochem. Int., **14**, 111-119 (1989); 4). Levant and Nemeroff, C. B., Current topics in Neuroendocrinology, **8**, 231-262 (1988)] and peripheral [Leeman, S. E., Aronin, N. and Ferris, C., Hormone Res., **38**, 93-132 (1982)] biological functions.

Neurotensin is also known to release mast cell histamine, indicating that antagonists will be useful in the treatment of allergic and inflammatory conditions, as well. [See, Rossei, S.S. and Miller, R.J., Life Sci., **31**, 509-516 (1982) and Kurose, M. and Saeki, K., Eur. J. Pharmacol., **76**, 129-136 (1981).]

Neurotensin, like most other peptides, is unable to cross the blood-brain barrier (BBB). However, certain peripheral effects of neurotensin have been observed after central administration of the peptide [Prange, A. J. and Nemeroff, C. B., Annal. NY Acad. Sciences, **400**, 368-391 (1982)]. The direct application of neurotensin into the brain causes hypothermia, potentiation of barbiturate induced sedation, catalepsy, antinociception, blockade of psychostimulant-induced

- 3 -

locomotor activity and reduced food consumption. In the central nervous system (CNS), neurotensin behaves as a neurotransmitter or neuromodulator [1) Uhl, G. R. and Snyder, S. H., Eur. J. Pharmacol., **41**, 89-91 (1977); 2) Uhl, G. R., Annal. NY Acad. Sciences, **400**, 132-149 (1982)], and has been shown to have close anatomical and
5 biochemical associations with the dopaminergic (DA) system [Nemeroff, C. B., et al. Annal. NY Acad. Sciences, **400**, 330-344 (1982)]. Neurotensin increases the synthesis and the turnover of DA in rat brain. Acute and chronic treatment with clinically efficacious antipsychotic drugs (e.g., haloperidol, chlorpromazine) have consistently
10 demonstrated an increase in neurotensin concentrations in the nucleus accumbens and striatum while phenothiazines that are not antipsychotics did not produce this increase. Behaviorally, neurotensin, after central administration, mimics the effects of systemically administered neuroleptics. However, unlike classical neuroleptics (which primarily
15 acts on D₂ receptors), neurotensin fails to bind to dopamine receptors or inhibit cAMP accumulation following DA receptor activation. Neurotensin does not block the stereotypy induced by DA agonists. The post-mortem studies of patients with schizophrenia showed an increase in the level of neurotensin in the Brodman's area 32 of human brain
20 [Nemeroff, C. B., et. al., Science, **221**, 972-975 (1983) and references cited therein], which suggest possible roles of neurotensin in the pathophysiology of this disease. Neurotensin receptors have also been implicated in Parkinson's disease and progressive supranuclear palsy [Chinaglia, G. et al., Neuroscience, **39**, 351-360 (1990)].
25 Of the total body neurotensin in many mammalian species, more than 80% is present in the gastrointestinal tract, especially in the distal small intestine in the endocrine like N-cells. In the gut, neurotensin stimulates pancreatic secretion [Sakamoto, T., et al, Surgery, **96**, 146-53 (1984)], inhibits gastric acid secretion and gastric emptying
30 [Blackburn, A. M., Lancet, **1**, 987-989 (1980)]. Neurotensin also stimulates the growth of small intestinal mucosa in an isolated defunctional loop of jejunum, which suggests a direct systemic effect of neurotensin in the gut. In addition, neurotensin can stimulate pancreatic

- 4 -

exocrine secretion in mammals [Iwatsuki, K., et al., Clin. Expt. Pharmacol. Physiol., **18**, 475-481 (1991) and references cited therein].

From the structural work, it is evident that the biological activity of neurotensin resides within the carboxy terminal five or six amino acid residues. The C-terminal hexapeptide NT⁸⁻¹³ has displayed
5 full biological activity of the tridecapeptide. In contrast, all amino terminal partial sequences are essentially inactive [Leeman, S. E. and Carraway, R. E., Annal. NY Acad. Sciences, **400**, 1-16 (1982)]. The C-terminal COOH group and two Arg residues are essential for the biological activity of NT⁸⁻¹³ as well as neurotensin. L-amino acids are
10 required at positions-9,10,11 and 13, and only Arg⁸ can be replaced by D-Arg without loss of any activity. At the position-11, an aromatic amino acid is essential. Similarly, alkyl side-chains of Ile¹² and Leu¹³ are also necessary for full biological activity [Kitabgi, P., Annal. NY Acad. Sciences, **400**, 37-53 (1982)]. Most of the analogues of
15 neurotensin examined generally behaved as agonists. However, two analogues D-Trp¹¹-NT and Tyr(Me)¹¹-NT have displayed partial antagonist activity [Rioux, F. R., et al., Eur. J. Pharmacol., **66**, 373-379 (1980)].

Although there are reports of peptidic neurotensin
20 antagonists, none are clinically useful, due to their short biological half life and limited oral bioavailability.


A European Patent Application, EP 477,049, disclosing 3-carboxamido-1,2-pyrazoles as non-peptidic neurotensin antagonists recently published.
25

30

- 5 -

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to novel compounds of structural formula I:



or a pharmaceutically acceptable salt thereof,
wherein:

R¹ is:

- (a) -NHSO₂NHCOR⁹,
- (b) -NHCONHSO₂R⁹,
- (c) -SO₂NHR⁹,
- (d) -SO₂NHCOR⁹,
- (e) -SO₂NHCONR⁷R⁹, or
- (f) -SO₂NHCOOR⁹;

R^{2a} and R^{2b} are each independently:

- (a) H,
- (b) Cl, Br, I, F,
- (c) CF₃,
- (d) C₁-C₆-alkyl,

- 6 -

- (e) C₁-C₆-alkoxy,
(f) C₁-C₆-alkyl-S-,
(g) C₂-C₆-alkenyl,
(h) C₂-C₆-alkynyl,
(i) C₃-C₇-cycloalkyl,
5 (j) aryl, as defined in R⁴ below, or
(k) aryl-C₁-C₆-alkyl;

R^{3a} is:

- (a) H,
10 (b) Cl, Br, I, F,
(c) C₁-C₆-alkyl,
(d) C₁-C₆-alkoxy, or
(e) C₁-C₆-alkoxyalkyl;

15 R^{3b} is:

- (a) H,
(b) Cl, Br, I, F,
(c) C₁-C₆-alkyl,
(d) C₃-C₇-cycloalkyl,
20 (e) C₁-C₆-alkoxy,
(f) CF₃,
(g) C₂-C₆-alkenyl, or
(h) C₂-C₆-alkynyl;

25 R⁴ is:

- (a) H,
(b) C₁-C₆-alkyl optionally substituted with a substituent
selected from the group consisting of: C₁-C₄-alkoxy, aryl,
heteroaryl, -CON(R¹⁰)₂, -N(R¹⁰)₂, -O-COR¹⁰ and
30 -COR¹⁰ or
(c) aryl, wherein aryl is phenyl or naphthyl, either
unsubstituted or substituted with one or two substituents
selected from the group consisting of Cl, F, Br, I, N(R⁷)₂.

- 7 -

NR⁷COOR⁹, NR⁷CONR⁷R⁹, CO₂R⁷, CONR⁷R⁹, C₁-C₄-alkyl, -(C₁-C₄)alkyl-Y, NO₂, OH, CF₃, C₁-C₄-alkoxy, -S(O)_x-(C₁-C₄)alkyl, and -(C₁-C₄)alkyl-N-(CH₂-CH₂)₂Q,

- (d) heteroaryl, wherein heteroaryl is defined as thiazole, imidazole, pyrazole, oxazole, isoxazole, pyridine, thiazine, quinoline, isoquinoline, phthalazine, quinazoline, pyridazine, pyrazine, or pyrimidine and wherein the heteroaryl is unsubstituted or substituted with one or two substituents selected from the group consisting of: -OH, -SH, -C₁-C₄-alkyl, -C₁-C₄-alkoxy, -CF₃, Cl, Br, F, I, -NO₂, -CO₂H, -CO₂-(C₁-C₄-alkyl), -NH₂, -NH(C₁-C₄-alkyl) and -N(C₁-C₄-alkyl)₂, NR⁷COOR⁹ and NR⁷CONR⁷R⁹,

(e) C₃-C₇-cycloalkyl, or

(f) -COaryl;

Q is: a single bond, -CH₂-, O, NR⁷, or S(O)_x;

Y is: COOR⁹, CN, NR⁷COOR⁹ or CONR⁷R⁹;

R⁵ and R⁶ are independently:

- (a) H,
 (b) C₁-C₆-alkyl, unsubstituted or substituted with a substituent selected from the group consisting of: -OH, -guanidino, C₁-C₄-alkoxy, -N(R⁷)₂, COOR⁷, -CON(R⁷)₂, -O-COR⁷, -aryl, -heteroaryl, -S(O)_x-R⁹, -tetrazol-5-yl, -CONHSO₂R⁹, -SO₂NH-heteroaryl, -SO₂NHCOR⁹, -PO(OR⁷)₂, -PO(OR⁸)R⁷, -SO₂NH-CN, -NR⁸COOR⁹, morpholino, N-(C₁-C₆-alkyl)-piperazine, and -COR⁷,
 (c) -CO-aryl,
 (d) -C₃-C₇-cycloalkyl,
 (e) Cl, Br, I, F,
 (f) -OH,
 (g) -OR⁹,

- 8 -

- (h) -C₁-C₄-perfluoroalkyl,
 (i) -S(O)_x-R⁹,
 (j) -COOR⁷,
 (k) -SO₃H,
 (l) -NR⁷R⁹,
 5 (m) -NR⁷COR⁹,
 (n) -NR⁷COOR⁹,
 (o) -SO₂NR⁷R⁸,
 (p) -NO₂,
 10 (q) -NR⁷SO₂R⁹,
 (r) -NR⁷CONR⁷R⁹,
 (s) -OCONR⁹R⁷,
 (t) -aryl,
 (u) -NHSO₂CF₃,
 15 (v) -SO₂NH-heteroaryl,
 (w) -SO₂NHCOR⁹,
 (x) -CONHSO₂R⁹,
 (y) -PO(OR⁷)₂,
 (z) -PO(OR⁸)R⁷,
 20 (aa) -tetrazol-5-yl,
 (bb) -CONH(tetrazol-5-yl),
 (cc) -COR⁷,
 (dd) -SO₂NHCN,
 (ee) -CO-heteroaryl,
 25 (ff) -NR⁷SO₂NR⁹R⁷,
 (gg) -N[CH₂CH₂]₂NR¹¹,
 (hh) -N[CH₂CH₂]₂O, or
 (ii) -heteroaryl as defined above;

30 x is: 0, 1, or 2,

R⁷ is: H, C₁-C₅-alkyl, aryl, or -CH₂-aryl;

- 9 -

R^8 is: H, or C_1 - C_4 -alkyl;

R^9 is:

- (a) aryl,
 (b) heteroaryl,
 5 (c) C_3 - C_7 -cycloalkyl,
 (d) C_1 - C_8 -alkyl, wherein alkyl is unsubstituted or substituted with one or two substituents selected from the group consisting of: aryl, heteroaryl, -OH, -SH, C_1 - C_4 -alkyl, -O(C_1 - C_4 -alkyl), -S(C_1 - C_4 -alkyl), -CF₃, Cl, Br, F, I, -NO₂, -CO₂H, -CO₂- C_1 - C_4 -alkyl, -NH₂, -NR⁷CO₂R¹⁰, -NH(C_1 - C_4 -alkyl), -N(C_1 - C_4 -alkyl)₂, -PO₃H₂, -PO(OH)(O- C_1 - C_4 -alkyl), -PO(OR⁸)R⁷, -NR⁷COR¹⁰, -CONR⁷R¹⁰, -OCONR⁷R¹⁰, -SO₂NR⁷R¹⁰, -NR⁷SO₂R¹⁰,
 10 -N(CH₂-CH₂)₂Q and -CON(CH₂-CH₂)₂Q or
 15 (e) perfluoro- C_1 - C_4 -alkyl;

R^{10} is:

- (a) aryl,
 20 (b) heteroaryl,
 (c) C_1 - C_6 -alkyl, wherein alkyl is unsubstituted or substituted with a substituent selected from the group consisting of: aryl, heteroaryl, -OH, -NH₂, -NH(C_1 - C_4 -alkyl), -N(C_1 - C_4 -alkyl)₂, -CO₂R⁷, Cl, Br, F, I, and -CF₃, or
 25 (d) perfluoro- C_1 - C_4 -alkyl;

R^{11} is: C_1 - C_6 -alkyl, C_3 - C_7 -cycloalkyl, -CONR⁷R⁸, heteroaryl, phenyl, -CO- C_3 - C_7 -cycloalkyl, or -CO- C_1 - C_6 -alkyl; and

30

r is: 1 or 2.

- 10 -

One embodiment of the compounds of formula (I) are those compounds wherein:

R¹ is:

- 5 (a) -NHSO₂NHCOR⁹, or
(b) -NHCONHSO₂R⁹;

R^{2a} is: H;

- 10 R^{2b} is: H, F, Cl, CF₃, C₁-C₆-alkyl, C₂-C₄-alkenyl, or
C₂-C₄-alkynyl, aryl or aryl-C₁-C₆-alkyl;

R^{3a} is: H;

- 15 R^{3b} is: H, F, Cl, CF₃, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-
alkynyl, or C₅-C₆-cycloalkyl;

R⁵ and R⁶ are each independently:

- 20 (a) H,
(b) C₁-C₆-alkyl unsubstituted or substituted with COOR⁷,
OCOR⁷, OH, or aryl,
(c) -OH,
(d) -NO₂,
(e) -NHCOR⁹,
25 (f) -C₁-C₄-alkoxy,
(g) -NHCO₂R⁹,
(h) -NR⁷R⁹,
(i) -Cl, F, Br,
(j) -CF₃,
30 (k) -CO₂R⁷,
(l) -CO-aryl,
(m) -S(O)_x-C₁-C₄-alkyl,
(n) -SO₂-NH-C₁-C₄-alkyl,
(o) -SO₂-NH-aryl,

- 11 -

- (p) $-\text{NHSO}_2\text{CH}_3$,
(q) $-\text{aryl}$,
(r) $-\text{NHCONR}^7\text{R}^9$,
(s) $-\text{N}[\text{CH}_2\text{CH}_2]_2\text{NR}^{11}$, or
(t) $-\text{N}[\text{CH}_2\text{CH}]_2\text{O}$;

5

r is one.

A class of this embodiment are those compounds of
Formula (I) wherein:

10

R^1 is:

- (a) $-\text{NHSO}_2\text{NHCOR}^9$, or
(b) $-\text{NHCONHSO}_2\text{R}^9$;

15

R^4 is: $(\text{C}_1\text{-C}_6)\text{-alkyl}$, aryl , $\text{aryl-(C}_1\text{-C}_6)\text{-alkyl}$, or
heteroaryl as defined before; and

R^5 and R^6 are each independently:

20

H , $-\text{C}_1\text{-C}_4\text{-alkyl}$, $-\text{aryl}$, $-\text{NO}_2$, $-\text{NR}^7\text{R}^9$, $-\text{NHCOOR}^9$, $-\text{Cl}$,
 $-\text{CH}_2\text{COOH}$, $-\text{S(O)}_x\text{-C}_1\text{-C}_4\text{-alkyl}$, $\text{NHCONR}^7\text{R}^9$,
 NHCOR^9 , CO_2R^9 , $-\text{F}$, $\text{N}[\text{CH}_2\text{CH}_2]_2\text{NR}^{11}$, or
 $\text{N}[\text{CH}_2\text{CH}_2]_2\text{O}$.

25

A second embodiment of the invention are the compounds
of formula (I) wherein:

R^1 is:

30

- (a) $-\text{SO}_2\text{NHR}^9$,
(b) $-\text{SO}_2\text{NHCOR}^9$,
(c) $-\text{SO}_2\text{NHCONR}^7\text{R}^9$, or
(d) $-\text{SO}_2\text{NHCOOR}^9$;

- 12 -

R^{2a} is: H;

R^{2b} is: H, F, Cl, CF₃, C₁-C₆-alkyl, C₂-C₄-alkenyl, or
C₂-C₄-alkynyl, aryl or aryl-C₁-C₆-alkyl

5 R^{3a} is: H;

R^{3b} is: H, F, Cl, CF₃, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-
alkynyl, or C₅-C₆-cycloalkyl;

10 R⁵ and R⁶ are independently:

- (a) H,
- (b) C₁-C₆-alkyl unsubstituted or substituted with
COOR⁷, OCOR⁷, OH, or aryl,
- (c) -OH,
- (d) -NO₂,
- (e) -NHCOR⁹,
- (f) -C₁-C₄-alkoxy,
- (g) -NHCO₂R⁹,
- (h) -NR⁷R⁹,
- (i) -Cl, F, Br,
- (j) -CF₃,
- (k) -CO₂R⁷,
- (l) -CO-aryl,
- (m) -S(O)_x-C₁-C₄-alkyl,
- (n) -SO₂-NH-C₁-C₄-alkyl,
- (o) -SO₂-NH-aryl,
- (p) -NHSO₂CH₃,
- (q) -aryl,
- (r) -NHCONR⁷R⁹,
- (s) -N[CH₂CH₂]₂NR¹¹, or
- (t) -N[CH₂CH₂]₂O; and

r is: one.

- 13 -

A class of this embodiment are those compounds of Formula (I) wherein:

R¹ is:

- 5 (a) -SO₂NHR⁹,
(b) -SO₂NHCOR⁹,
(c) -SO₂NHCONR⁷R⁹, or
(d) -SO₂NHCOOR⁹;

10 R⁴ is: (C₁-C₆)alkyl, aryl, aryl-(C₁-C₆)alkyl, or heteroaryl;
and

R⁵ and R⁶ are each independently:

15 H, -C₁-C₄-alkyl, -aryl, -NO₂, -NR⁷R⁹, -NHCOOR⁹, -
Cl, -CH₂COOH, -S(O)_x-C₁-C₄-alkyl, NHCONR⁷R⁹,
NHCOR⁹, CO₂R⁹, -F, N[CH₂CH₂]₂NR¹¹, or
N[CH₂CH₂]₂O.

20


25

30

- 14 -

Further exemplifying this class are the compounds indicated in Table I below.

TABLE I



	<u>Cmpd. #</u>	<u>R⁴</u>	<u>R⁵</u>	<u>R⁶</u>	<u>R⁹</u>
20	1	H	H	H	-(CH ₂) ₅ NHBoc
	2	H	H	H	-(CH ₂) ₅ NH ₂
	3	Methyl	H	H	-(CH ₂) ₅ NHBoc
	4	Methyl	H	H	-(CH ₂) ₅ NH ₂
25	5	n-Propyl	H	i-propyl	-(CH ₂) ₅ NHBoc
	6	n-Propyl	H	H	-(CH ₂) ₅ NHBoc
	7	n-Propyl	H	H	-(CH ₂) ₅ NH ₂
	8	i-Propyl	H	H	-cyclopropyl
	9	i-Propyl	H	H	-(CH ₂) ₄ NHBoc
30	10	i-Propyl	H	H	-(CH ₂) ₄ NH ₂
	11	Phenyl	H	H	-cyclopropyl
	12	Phenyl	H	H	-(CH ₂) ₅ NHBoc
	13	Phenyl	H	H	-(CH ₂) ₅ NH ₂
	14	Phenyl	methyl	H	-(CH ₂) ₅ NHBoc

- 15 -

	<u>Cmpd. #</u>	<u>R⁴</u>	<u>R⁵</u>	<u>R⁶</u>	<u>R⁹</u>
	15	Phenyl	methyl	H	-(CH ₂) ₅ NH ₂
	16	p-Toluyyl	H	H	-(CH ₂) ₅ NHCOCH ₃
	17	p-Toluyyl	H	methyl	-(CH ₂) ₅ NH ₂
	18	p-Toluyyl	H	methyl	-(CH ₂) ₅ NHBoc
5	19	4-Cl-Phenyl	H	H	-(CH ₂) ₅ NHBoc
	20	4-Cl-Phenyl	H	H	-(CH ₂) ₅ NH ₂
	21	4-Cl-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	22	4-Cl-Phenyl	H	methyl	-(CH ₂) ₅ NHBoc
	23	4-Br-Phenyl	H	H	-(CH ₂) ₅ NHBoc
10	24	4-Br-Phenyl	H	H	-(CH ₂) ₅ NH ₂
	25	4-F-Phenyl	H	H	(CH ₂) ₅ NHBoc
	26	4-F-Phenyl	H	H	(CH ₂) ₅ NH ₂
	27	4-OMe-Phenyl	H	H	-(CH ₂) ₅ NHBoc
	28	4-OMe-Phenyl	H	H	-(CH ₂) ₅ NH ₂
15	29	p-Toluyyl	H	H	-(CH ₂) ₅ NHBoc
	30	p-Toluyyl	H	H	(CH ₂) ₅ NH ₂
	31	p-Toluyyl	H	H	(CH ₂) ₆ NHBoc
	32	p-Toluyyl	H	H	(CH ₂) ₆ NH ₂
	33	p-Toluyyl	H	H	-(CH ₂) ₃ NHBoc
20	34	p-Toluyyl	H	H	-(CH ₂) ₃ NH ₂
	35	p-Toluyyl	H	H	-(CH ₂) ₄ NHBoc
	36	p-Toluyyl	H	H	-(CH ₂) ₄ NH ₂
	37	p-Toluyyl	H	H	-(CH ₂) ₆ OH
	38	p-Toluyyl	H	H	-(CH ₂) ₅ COOC ₂ H ₅
25	39	p-Toluyyl	H	H	-(CH ₂) ₄ COOH
	40	p-Toluyyl	methyl	H	-(CH ₂) ₅ COOC ₂ H ₅
	41	p-Toluyyl	H	H	-(CH ₂) ₆ CH ₃
	42	p-Toluyyl	H	H	-(CH ₂) ₅ CONHCH ₃
	43	p-Toluyyl	H	H	-(CH ₂) ₅ CON(CH ₃) ₂
30	44	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	45	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂) ₄

- 16 -

	<u>Cmpd. #</u>	<u>R⁴</u>	<u>R⁵</u>	<u>R⁶</u>	<u>R⁹</u>
	46	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂) ₅
	47	p-Toluyyl	H	H	-(CH ₂) ₄ -CON(CH ₂ CH ₂) ₂ O
	48	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂ CH ₂) ₂ NH
	49	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂ CH ₂) ₂ NAc
5	50	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂ CH ₂) ₂ NCH ₃
	51	p-Toluyyl	H	H	-(CH ₂) ₆ CON(CH ₃) ₂
	52	p-Toluyyl	H	H	-(CH ₂) ₂ CH(NHBoc)COOtBu
	53	p-Toluyyl	H	H	-2-thienyl
	54	p-Toluyyl	H	H	-3-furyl
10	55	p-Toluyyl	H	H	-2-furyl
	56	p-Toluyyl	H	H	-(CH ₂) ₂ OCH ₃
	57	p-Toluyyl	H	H	-NH(CH ₂) ₃ CH ₃
	58	p-Toluyyl	H	H	-NH(CH ₂) ₅ CH ₃
	59	p-Toluyyl	H	H	-NH(CH ₂) ₃ Cl
15	60	p-Toluyyl	H	H	-NH(CH ₂) ₂ -2-thienyl
	61	p-Toluyyl	H	H	-CH ₂ OCH ₂ CH ₃
	62	p-Toluyyl	H	H	-(CH ₂) ₅ OH
	63	p-Toluyyl	H	H	-NH(CH ₂) ₅ CH ₃
	64	p-Toluyyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
20	65	p-Toluyyl	H	H	-(CH ₂) ₅ NHCH ₃
	66	1-Naphthyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
	67	1-Naphthyl	H	H	-(CH ₂) ₅ CON(CH ₃) ₂
	68	1-Naphthyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	69	1-Naphthyl	H	H	-(CH ₂) ₅ NHBoc
25	70	1-Naphthyl	H	H	-(CH ₂) ₅ NH ₂
	71	4-OMe-Phenyl	H	H	-(CH ₂) ₅ CON(CH ₃) ₂
	72	4-OMe-Phenyl	H	H	(CH ₂) ₄ CON(CH ₃) ₂
	73	2-Naphthyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
	74	2-Naphthyl	H	H	-(CH ₂) ₅ CON(CH ₃) ₂
30	75	2-Naphthyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	76	2-Naphthyl	H	H	-(CH ₂) ₅ NHBoc
	77	2-Naphthyl	H	H	-(CH ₂) ₅ NH ₂

- 17 -

	<u>Cmpd. #</u>	<u>R⁴</u>	<u>R⁵</u>	<u>R⁶</u>	<u>R⁹</u>
	78	Pentamethylphenyl	H	H	-(CH ₂) ₅ NH ₂
	79	Pentamethylphenyl	H	H	-(CH ₂) ₅ NHBoc
	80	Pentamethylphenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
5	81	2-pyridyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	82	4-pyridyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	83	2-Thienyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	84	2-pyridyl	H	H	-(CH ₂) ₅ NHBoc
	85	2-pyridyl	H	H	-(CH ₂) ₅ NH ₂
10	86	2-pyridyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
	87	4-pyridyl	H	H	-(CH ₂) ₅ NHBoc
	88	4-pyridyl	H	H	-(CH ₂) ₅ NH ₂
	89	4-pyridyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
	90	4-pyridyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
15	91	2-Thienyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	92	4-(N-Morpholinomethyl)- phenyl	H	H	-(CH ₂) ₅ NHBoc
	93	4-(N-Morpholinomethyl)- phenyl	H	H	-(CH ₂) ₅ NH ₂
20	94	4-(N-Pyrrolidinomethyl)- phenyl	H	H	-(CH ₂) ₅ NHBoc
	95	4-(N-Pyrrolidinomethyl)- phenyl	H	H	-(CH ₂) ₅ NH ₂
	96	4-(N-Pyrrolidinomethyl)- phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
25	97	4-(N-Morpholinomethyl)- phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	98	p-Toluyyl	H	H	-(CH ₂) ₃ CON(CH ₃) ₂
	99	p-Toluyyl	H	H	-(CH ₂) ₅ NHCON(CH ₃) ₂
30					

- 18 -

Cmpd. #	R ⁴	R ⁵	R ⁶	R ⁹
100	p-ToluyI	H	H	-(CH ₂) ₅ NHSO ₂ iPr
101	p-ToluyI	H	H	-(CH ₂) ₃ NHCON(CH ₃) ₂
102	p-ToluyI	H	H	-NH(CH ₂) ₃ CON(CH ₃) ₂
103	p-ToluyI	H	H	-(CH ₂) ₃ NHCOCH ₃
5 104	p-ToluyI	H	H	-(CH ₂) ₄ CONH ₂
105	p-ToluyI	H	H	-(CH ₂) ₄ CONHCH ₃
106	4-Cl-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
107	4-F-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
108	2-CH ₃ CONH-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂

10

The terms "alkyl", "alkenyl", "alkynyl": and the like include both the straight chain and branched chain species of these generic terms wherein the number of carbon atoms in the species permit. Unless otherwise noted, the specific names for these generic terms shall mean the straight chain species. For example, the term "butyl" shall mean the normal butyl substituent, n-butyl.

15

For a general review of synthesis and reactivity of substituted phthalazinones and related compounds, see - M. Tishler and B. Stanovnik, Comprehensive Heterocyclic Chemistry, Vol. 3 (part 2B), 1-56 (1984) Eds: A. J. Boulton and A. Mckillop; Pergamon Press., and also N. R. Patel, Heterocyclic Compounds, Vol. 27, Chapter II, pages 376-446 (1973). Ed: R. N Castle, John Wiley & Sons, and references cited therein.

20


Scheme 1 illustrates the preferred method for the preparation of substituted phthalazin-1-(2H)-ones. An appropriately substituted 2-acylbenzoic acid 1 or a similar starting material is reacted with hydrazine hydrate in an appropriate solvent such as an alcohol or acetic acid under reflux for 2-24 h to form the corresponding substituted phthalazin-1-(2H)-one 2.

25

30

- 19 -

Scheme 1




Where R⁴ is H, alkyl or aryl, as defined before.

The keto acid 1 may be prepared from the appropriately substituted 2-bromobenzoic acid or a similar starting material using the methods described in the literature [W. E. Parham, C. K. Bradsher, K. J. Edger, *J. Org. Chem.*, **46**(6), 1057(1981) and references cited therein]. Alternatively, the keto acids may also be synthesized by procedures described by R. L. Shriner *et al.*, *J. Org. Chem.*, **16**, 1064 (1951), and C. R. Hauser *et al.*, *J. Org. Chem.*, **23**, 861 (1958).

A general method for the preparation of 2-alkyl-phthalazin-1-(2H)-ones of Formula I is illustrated in Scheme 2. An appropriately substituted phthalazin-1-(2H)-one 2 is alkylated with the appropriate alkyl halide 3 (or pseudo halide, such as tosylate, mesylate, triflate and the like) in the presence of an appropriate base such as alkali metal hydrides, carbonates, bicarbonates or an organic base (e.g., trialkylamines, morpholine and the like) in an appropriate polar solvent, such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran, lower alkyl alcohols and the like. The alkylated material 4 may then be transformed into the desired compound of Formula I by removal of the protecting group present in R^{1a} followed by further transformation of the functional group, thus formed, into the desired R¹ group. Similarly, the R^{1a} may also be directly transformed into the desired R¹ to give the compound of formula I.


- 20 -

Scheme 2

The biphenyl alkylating agents 3 can be synthesized using the reactions and techniques described in published US Patent No. 5,126,342 (Merck & Co, Inc.).

- 21 -


Compounds of Formula I in which R^1 is SO_2NHR^9 or SO_2NHCOR^9 may be prepared according to the general methods described for such transformations in US Patent 5,126,342. More specifically these compounds may be prepared as outlined in Scheme 3.

Scheme-3

The protected sulfonamide 5 (prepared as described in Scheme 2 using the alkylating agent 3, where R^{1a} is $-SO_2NH-tBu$) is reacted with TFA, and the resulting free sulfonamide 6 is acylated with an appropriate acylimidazole (generated from the corresponding R^9COOH and carbonyldiimidazole) in the presence of DBU to form the acylsulfonamide 7.

- 22 -

Compounds of Formula I in which R^1 is $\text{SO}_2\text{NHCOOR}^9$ or $\text{SO}_2\text{NHCONR}^7\text{R}^9$ may be prepared according to methods outlined in Schemes 4 and 5.


Scheme-4

25 The sulfonamide 6 may be reacted with an appropriate isocyanate (R^9NCO) or carbamoyl chloride ($\text{R}^7\text{R}^9\text{NCOCl}$) in the presence of an appropriate base to form the corresponding sulfonylureas 8.

30

- 23 -

Scheme-5




Similarly, the sulfonamide **6** may be reacted with an appropriate alkyl or aryl chloroformate ($R^9OCOC(=O)Cl$) in the presence of an appropriate base such as pyridine to form the corresponding sulfonylcarbamate **9**.

Compounds of Formula I, where R^1 is $-NHSO_2NHCOR^9$ may be prepared from the corresponding nitro precursor **10** (prepared according to Scheme 2, where $R^{1a} = NO_2$) as outlined in Scheme 6. The nitro group in **10** is reduced to the corresponding amine **11** which may then be reacted with t-butylsulfamoyl chloride to give the N-t-butylsulfamide **12**. Removal of the t-butyl group followed by acylation may produce the desired acylsulfamides **13**. Similarly, compound **12** may be reacted with an appropriate N-acylsulfamoyl chloride to give **13**.

- 24 -

Scheme-6



- a. $\text{H}_2/\text{Pd-C}$ or, SnCl_2/HCl b. $t\text{-BuNHSO}_2\text{Cl}$ c. $\text{R}^9\text{CONHSO}_2\text{Cl}$
- d. i) TFA ii) aq. NaHCO_3 iii) $\text{R}^9\text{CO-X}$

- 25 -

The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformation being effected. It is understood by those skilled in the art of organic synthesis that the functionality present on the heterocycle and in the reactants being employed should be consistent with the chemical transformations being conducted. Depending upon the reactions and techniques employed, optimal yields may require changing the order of synthetic steps or use of protecting groups followed by deprotection.

The compounds of this invention form salts with various inorganic and organic acids and bases which are also within the scope of the invention. Such salts include ammonium salts, alkali metal salts like sodium and potassium salts, alkaline earth metal salts like the calcium and magnesium salts, salts with organic bases; e.g., dicyclohexylamine salts, N-methyl-D-glutamine salts, salts with amino acids like arginine, lysine, and the like. Also, salts with organic and inorganic acids may be prepared; e.g., HCl, HBr, H₂SO₄, H₃PO₄, methanesulfonic, toluenesulfonic, maleic, fumaric, camphorsulfonic. The nontoxic, physiologically, acceptable salts are preferred, although other salts are also useful in isolating and/or purifying the product.

The salts can be formed by conventional means, such as by reacting the free acid or free base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the cations of an existing salt for another cation on a suitable ion exchange resin.

Neurotensin is a peptide hormone and the assays described below have been developed to identify neurotensin antagonists and to determine their efficacy in vitro. The following three assays have been employed for that purpose.

30

- 26 -

RAT FOREBRAIN RECEPTOR ASSAY

Male rats are sacrificed by decapitation following ether anesthetization. Forebrains are homogenized using a polytron in 20 volumes 50 mM Tris HCl, pH 7.4, and centrifuged at 50,000 x g for 20 min. The final pellet is washed twice by rehomogenization and centrifugation as before. The final pellet is resuspended at a concentration of 8 mg tissue (wet weight) per 0.750 ml of 50 mM Tris HCl, pH 7.4, which also contains 1 mM EDTA, 4 mg/ml bacitracin, 5 mM levocabastine HCl, 1mM phenanthroline, 10 mg/ml soybean trypsin inhibitor and 100 mM phenyl methyl sulfonyl fluoride. Assay tubes (13 X 100 mm polypropylene) receive 1) 100 µl buffer or 10 mM neurotensin (for non-specific binding) 2) 100 µl of 60 pM [¹²⁵I]neurotensin 3) 20 µl test compounds 4) 750 µl tissue suspension and 5) enough buffer to bring final volume to 1 ml. After 30 minutes at room temp, the samples are filtered using a Brandel M24 cell harvester with GF/B filtermats that have been presoaked in 0.2% polyethyleneimine for 2 hours. The tubes are rinsed with 3 X 4 ml of ice cold 10 mM Tris buffer (pH 7.4 at room temperature). The filter discs are placed in 12 X 75 mm polypropylene tubes for counting on a Packard Multi-Prias gamma counter.

HUMAN HT-29 CELL MEMBRANE ASSAY

HT-29 cells were routinely grown in 225 cm² Costar tissue culture flasks at 37°C in a humidified atmosphere of 5% CO₂/95% air in Dulbecco's modified Eagle's medium with high glucose containing 50 U/ml penicillin, 50 mg/ml streptomycin, 5% fetal bovine serum and 5% newborn calf serum. Cells were subcultured with 0.25% trypsin at a ratio of 1:6 with confluence being reached at 48 to 72 hrs. Cells from confluent flasks (approx. 1 x 10⁸ cells/flask) were harvested by scraping. The cells were pelleted by centrifugation (1000 x g, 5 min), resuspended in 50 mM Tris HCl, pH 7.4, and homogenized with a polytron (setting 7 for 10 sec.). Cell membranes were washed twice by centrifugation (50,000 x g, 15 min) and rehomogenized. The resulting pellet was either frozen at -70°C for future use or run directly in the

- 27 -

assay by resuspending at a concentration of 0.5×10^6 cells per 0.750 ml of assay buffer (50 mM Tris HCl, pH 7.4, containing 1 mM EDTA, 40 mg/ml bacitracin, 1 mM phenanthroline, 10 mg/ml soybean trypsin inhibitor and 100 mM phenylmethylsulfonyl fluoride).

5 Assay tubes (13 x 100 mm polypropylene) receive 1) 100 μ l buffer or 10 mM neurotensin (for non-specific binding) 2) 100 μ l of 60 pM [125 I]neurotensin 3) 20 μ l test compounds 4) 750 μ l cell membrane suspension and 5) enough buffer to bring final volume to 1 ml. After 30 minutes at room temperature, the samples are filtered using a Brandel M24 cell harvester with GF/B filtermats that have been
10 presoaked in 0.2% polyethyleneimine for 2 hours. The tubes are rinsed with 3 x 4 ml of ice cold 10 mM Tris buffer (pH 7.4 at room temperature). The filter discs are placed in 12 x 75 mm polypropylene tubes for counting on a Packard Multi-Prias gamma counter. [The above assay is derived from the assay described in Kitabgi, P. *et al.*,
15 Molecular Pharmacology, 18, 11-19 (1980)].

NEUROTENSIN BINDING ASSAY TO HUMAN FRONTAL CORTEX

20 Post-mortem human brain is obtained through the National Disease Research Interchange (Philadelphia, PA). The donors were without psychiatric or neurological abnormalities. Frontal cortex is dissected free of white matter and homogenized using a polytron in 20 volumes 50 mM Tris HCl, pH 7.4, and centrifuged at 50,000 x g for 20 min. The resulting pellet is washed twice by rehomogenization and
25 centrifugation as before. The final pellet is resuspended at a concentration of 8 mg tissue (wet weight) per 0.750 ml of 50 mM Tris HCl, pH 7.4, which also contains 1 mM EDTA, 4 mg/ml bacitracin, 1 mM phenanthroline, 10 mg/ml soybean trypsin inhibitor and 100 mM phenyl methyl sulfonyl fluoride. Assay tubes (13 x 100 mm
30 polypropylene) receive 1) 100 μ l buffer or 10 mM neurotensin (for non-specific binding) 2) 100 μ l of 60 pM [125 I]neurotensin 3) 20 μ l test compounds 4) 750 μ l tissue suspension and 5) enough buffer to bring final volume to 1 ml. After 30 minutes at room temp, the samples are filtered using a Brandel M24 cell harvester with GF/B

- 28 -

filtermats that have been presoaked in 0.2% polyethyleneimine for 2 hours. The tubes are rinsed with 3 x 4 ml of ice cold 10mM Tris buffer (pH 7.4 at room temperature). The filter discs are placed in 12 x 75 mm polypropylene tubes for counting on a Packard Multi-Prias gamma counter.

5 Using the methodology described above, representative compounds of the invention were evaluated and all were found to exhibit an activity of at least $IC_{50} < 50 \mu M$ thereby demonstrating and confirming the utility of the compounds of the invention as effective neurotensin antagonists.

10 Thus, the compounds of the present invention are useful in attenuating the effect of peptide hormone neurotensin, and hence in the treatment of conditions that are caused by altered levels of neurotensin in humans. These compounds are of value in the treatment of a variety of central nervous system disorders, such as psychoses, depression,
15 Alzheimer's disease and anxiety. These compounds may also be expected to be useful in the treatment of gastrointestinal disorders such as gastroesophageal reflux disorder (GERD), irritable bowel syndrome, diarrhea, cholic, ulcer, GI tumors, dyspepsia, pancreatitis and esophagitis.

20 About 1 to 100 mg. of compound or mixture of compounds of Formula I or a physiologically acceptable salt is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in
25 these compositions or preparations is such that a suitable dosage in the range indicated is obtained.

 Illustrative of the adjuvants which can be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as
30 microcrystalline cellulose; a disintegrating agent such as corn starch, pregelatinized starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. When the unit dosage unitform is a capsule, it may contain, in

- 29 -

addition to materials of the above type, a liquid carrier such as fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection, a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or a synthetic fatty vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like can be incorporated as required.

The following examples illustrate the preparation of the compounds of formula (I) and their incorporation into pharmaceutical compositions and as such are not to be considered as limiting the invention set forth in the claims appended hereto.

All ^1H -NMR spectra were recorded on a Varian XL-200 or XL-400 Fourier Transform spectrometer. Chemical shifts are reported as (parts per million) downfield from tetramethylsilane. Mass spectra were obtained from the Merck & Co, Inc. mass spectral facility in Rahway, N.J.. Analytical TLC was conducted on E. M. Merck precoated silica plates (0.25 mm on glass, Kieselgel 60 F254) with UV and/or iodine visualization. Flash chromatography was conducted using E. Merck silica gel (mesh 200-400). All reactions were carried out under an atmosphere of dry nitrogen under standard conditions unless specified otherwise.

30

- 30 -

EXAMPLE 1SYNTHESIS OF PHTHALAZIN-1(2H)-ONES: (A GENERAL DESCRIPTION):

5 To a suspension or a solution of an appropriate 2-acylbenzoic acid (available from a commercial source or prepared according to the literature procedure cited earlier)(1 mMol) in ethanol (5 ml) was added hydrazine hydrate (5 mMol), and the resulting mixture was refluxed for 2-6 h. The reaction was cooled to room
10 temperature, and the solid precipitated was filtered, washed with water and then cold ethanol. The resulting solid was dried in vacuo to give the desired phthalazin-1-(2H)-one which was crystallized from ethanol or any other appropriate solvent. Alternatively, the reaction mixture was
15 concentrated to give the crude product which was then purified by trituration with water followed by crystallization from an appropriate solvent to give the desired phthalazin-1-(2H)-one.


20

25

30

- 31 -

Table II lists representative examples of phthalazin-1(2H)-ones prepared according to the procedure outlined in Example 1.

Table II2

<u>Compound #</u>	<u>R⁴</u>	<u>Melting Point</u> ^a
2A	methyl	221-222°C (ethanol)
2C	phenyl	232-233°C (ethanol)
2D	p-toluy	259-260°C (ethanol)
2E	(4-Cl)phenyl	267°C (toluene)
2F	1-naphthyl	261°C (ethanol)
2G	pentamethylphenyl	276°C
2H	2-pyridyl	¹ H-NMR, FAB MS: 224 (M+H)
2I	i-propyl	156-157°C (ethanol)
2J	(4-OMe)phenyl	240-241°C
2K	(4-F)phenyl	268°C
2L	H	¹ H-NMR, FAB MS: 147 (M+H)

^a Recrystallization solvent.

- 32 -

EXAMPLE 2

Preparation of 4-p-toluy-2-(2'-aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

- 5 Step 1. 4-p-toluy-2-(2'-t-butylaminosulfonyl)-biphen-4-yl)methyl-phthalazin-1-(2H)-one (Alkylation of substituted phthalazin-1-(2H)-one)
-

To a suspension of 4-p-toluy-phthalazin-1-(2H)-one [compound 2D] (2.36 g, 10 mMol) in toluene (50 mL) were added 2.5
10 N aqueous NaOH (4 mL) and Triton B (1 mL) followed by 2-(4'-bromomethylbiphenyl)-t-butylsulfonamide [prepared according to the procedure described in US patent 5126342] (4.2 g, 11 mMol). The mixture was stirred at 85°C for 12 h and then cooled to room
15 temperature. The reaction was diluted with ethylacetate (100 mL), and the organic phase was washed with water (3 X 50 mL), and then dried over MgSO₄. The ethylacetate layer was filtered and concentrated in vacuo to a small volume (~10 mL). Dry ether (100 mL) was added and the precipitate formed was filtered and dried. The crude product was
20 then recrystallized from hot ethylacetate to give the desired product 4-p-toluy-2-(2'-t-butylaminosulfonyl)-biphen-4-yl)methyl-phthalazin-1-(2H)-one as white crystalline solid (4.3 g).
1H-NMR (CDCl₃): δ 8.49 (m, 1H), 8.15 (d, 1H), 7.76 (m, 3H), 7.15-7.60 (m, 11 H), 5.50 (s, 2H), 3.51 (s, 1H), 2.45 (s, 3H), 0.91 (s, 9H).
FAB-MS: (m/e) 538 (M+H).

25

- Step 2. 4-p-toluy-2-(2'-aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one (Removal of the t-butyl group):

A solution of 4-p-toluy-2-(2'-t-butylaminosulfonyl)-biphen-4-yl)methyl-phthalazin-1-(2H)-one (2.7 g, 5.02 mMol) in
30 trifluoroacetic acid (20 mL) was stirred at room temperature for 12 -15 h. The solvent was removed in vacuo, and the residue was treated with cold aqueous saturated NaHCO₃. The precipitate formed was filtered and washed with water and then dried. The solid (2.4 g) was triturated with 50% ether in ethyl acetate (20 mL) at room temperature and

- 33 -

filtered to give the desired sulfonamide 4-p-toluy1-2-(2'-aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one as white amorphous solid (2.2 g).

¹H-NMR (CDCl₃): δ 8.49 (m, 1H), 8.15 (d, 1H), 7.76 (m, 3H), 7.15-7.60 (m, 11 H), 5.50 (s, 2H), 3.81 (s, 2H), 2.45 (s, 3H).

5 FAB-MS: (m/e) 482 (M+H).


Employing the procedures outlined above in Example 2, the following phthalazinone derivatives (Table III) were prepared.

10

Table III

15

20



25

30

<u>Examples</u>	<u>R⁴</u>	<u>NMR</u>	<u>Mass Spect</u>
<u>3</u>	phenyl	Yes	468(M+H)
<u>4</u>	(4-Cl)phenyl	Yes	502, 504(M+H)
<u>5</u>	pentamethylphenyl	Yes	538(M+H)
<u>6</u>	1-naphthyl	Yes	518(M+H)
<u>7</u>	methyl	Yes	406(M+H)
<u>8</u>	n-propyl	Yes	422(M+H)
<u>9</u>	2-pyridyl	Yes	469(M+H)

- 34 -

EXAMPLE 10ACYLATION OF SULFONAMIDE


5 4-p-toluy1-2-(2'-(6-(N-t-butoxycarbonyl)aminohexanoyl)-
aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

To a solution of 6-(N-t-butoxycarbonyl)aminohexanoic acid (2.88 g, 12.45 mMol) in dry tetrahydrofuran (THF) (25 mL) was added carbonyl diimidazole (2.1 g, 12.45 mMol). The mixture was
10 heated at 65°C for 3 h. After cooling to room temperature, a solution of the sulfonamide 4-p-toluy1-2-(2'-(6-(N-t-butoxy-carbonyl)amino-hexanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one (obtained in Example 2) (2.0 g, 4.15 mMol) and 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU) (1.86 mL, 12.45 mMol) in THF (20 mL) was
15 added. The solution was stirred at 50°C for 18 hr. then concentrated to dryness *in vacuo*. 5% Citric acid solution was added and the mixture extracted with ethyl acetate three times. The combined organic phase was washed with brine, dried (over magnesium sulfate) and the solvent removed *in vacuo*. The residue was pre-absorbed on silica gel and
20 purified by flash chromatography using chloroform-methanol-NH₄OH (150:10:1) to give the titled acyl sulfonamide as a white amorphous solid, which was recrystallized from diethyl ether/hexane (2.3 g).
¹H-NMR (CDCl₃): δ 8.50 (m, 1H), 8.22 (d, 1H), 7.78 (m, 3H), 7.15-7.60 (m, 11 H), 5.52 (s, 2H), 3.0 (m, 2H), 2.45 (s, 3H), 1.84 (t, 2H),
25 1.44 (s, 9H), 1.1-1.4 (m, 6H).
FAB-MS: (m/e) 695 (M+H).

The following analogs of 4-p-toluy1-2-(2'-(6-(N-t-butoxycarbonyl)aminohexanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one (Table IV) were prepared by using the procedure
30 described in Example 10.

- 35 -

Table IV



15

<u>Examples</u>	<u>R⁴</u>	<u>NMR</u>	<u>Mass Spect.</u>
<u>11</u>	phenyl	X	681(M+H)
<u>12</u>	(4-Cl)phenyl	X	715,717(M+H)
20 <u>13</u>	methyl	X	619(M+H)
<u>14</u>	n-propyl	X	647(M+H)

EXAMPLE 15

25 4-p-toluy1-2-(2'-(6-aminohexanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

To a solution of 4-p-toluy1-2-(2'-(6-(N-t-butoxycarbonyl)-aminohexanoyl)aminosulfonyl)biphen-4-yl)-methyl-phthalazin-1-(2H)-one (obtained in Example 10) (2.0 g, 2.88 mMol) in methylene chloride (10 mL) was added a saturated solution of hydrogen chloride in ethyl acetate (10 mL), and the mixture stirred at room temperature for 4 h. The volatile components of the mixture were removed *in vacuo* and the product was precipitated with dry ether. The hygroscopic solid

30

- 36 -


was filtered, washed with dry ether and dried *in vacuo*. The product was then recrystallized from (methanol/ether) to give the amine hydrochloride of the titled compound (1.8 g) as white powder.

¹H-NMR (CD₃OD): δ 8.50 (m, 1H), 8.22 (d, 1H), 7.78 (m, 3H), 7.15-7.60 (m, 11 H), 5.52 (s, 2H), 3.2 (m, 2H), 2.45 (s, 3H), 1.84 (t, 2H), 1.2 (m, 6H).

FAB-MS: (m/e) 595 (M+H).

Similarly, the following analogs of 4-p-toluy-2-(2'-(6-aminohexanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one (Example 15) were also prepared.

Table V



<u>Examples</u>	<u>R⁴</u>	<u>NMR</u>	<u>Mass spect.</u>
<u>16</u>	phenyl	X	581(M+H)
<u>17</u>	(4-Cl)phenyl	X	615,617(M+H)
<u>18</u>	methyl	X	519(M+H)
<u>19</u>	n-propyl	X	547(M+H)

- 37 -

EXAMPLE 20

4-p-toluy1-2-(2'-(6-(N,N-dimethylamino)hexanoyl)aminosulfonyl)-
biphen-4-yl)methyl-phthalazin-1-(2H)-one.

5 The amine (from Example 15) (10 mg, 0.017 mmol), 30% formaldehyde solution (1 mL) and formic acid (0.4 mL) were heated together at 100 °C for 2 hr. The mixture was concentrated to dryness *in vacuo*. The residue was pre-absorbed on silica gel and chromatographed (0 - 10% methanol/methylene chloride, 1% ammonia) to give the titled
10 dimethylamine compound (5.9 mg, 56%) (for spectral data see Table VI).

EXAMPLE 21

15 4-p-toluy1-2-(2'-(4-(N-t-butoxycarboxamido)butanoyl) aminosulfonyl)-
biphen-4-yl)methyl-phthalazin-1-(2H)-one.

 Carbonyl diimidazole (49 mg, 0.3 mmol) was added to a solution of t-BOC-aminobutyric acid (61 mg, 0.3 mmol) in tetrahydrofuran (THF) (3 mL) under nitrogen at room temperature.
20 The mixture was heated at 65 °C for 3 hr. After cooling to room temperature, a solution of the sulfonamide (obtained in Example 2) (48 mg, 0.1 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (37 µL, 0.25 mmol) in THF (3 mL) was added. The solution was heated at 50 °C
25 for 18 hr. then concentrated to dryness *in vacuo*. 5% Citric acid solution was added and the mixture extracted with ethyl acetate three times. The combined organic phase was washed with brine, dried (magnesium sulfate) and the solvent removed *in vacuo*. The residue was pre-absorbed on silica gel and chromatographed (0 - 10%
30 methanol/methylene chloride) to give the titled acyl sulfonamide which was recrystallized from diethyl ether/hexane (32 mg, 48%) (for spectral data see Table VI).

- 38 -

EXAMPLE 22

4-p-toluy1-2-(2'-(4-(N,N-dimethylcarboxamido)butanoyl)amino-sulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

5 The titled dimethyl amide was synthesized from the sulfonamide (Example 2) and dimethylamidobutyric acid using the procedure outlined for Example 21. Chromatography (0 - 5% methanol/methylene chloride) followed by recrystallization (ethyl acetate/diethyl ether) gave the desired dimethyl amide in 51% yield (for spectral data see Table VI).

10

EXAMPLE 23

4-p-toluy1-2-(2'-(5-ethoxycarbonyl-pentanoyl)aminosulfonyl) biphen-4-yl)methyl-phthalazin-1-(2H)-one.

15 The titled ethyl ester was synthesized from the sulfonamide (Example 2) and adipic acid *mono*-ethyl ester using the procedure outlined for Example 21. Chromatography (0 - 5% methanol/methylene chloride, 0.5% ammonia) followed by recrystallization (ethyl acetate/diethyl ether) gave the desired ethyl ester in 48% yield (for spectral data see Table VII).

20

EXAMPLE 24

25 4-p-toluy1-2-(2'-(5-carboxy-pentanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

2M Lithium hydroxide solution (0.9 mL) was added to a stirred solution of the ethyl ester (Example 23) (300 mg, 0.47 mmol) in THF (15 mL) and water (3 mL) at room temperature. After stirring for 3 hr., 2M lithium hydroxide solution (0.9 mL) was added and stirring continued for 18 hr. The solution was concentrated *in vacuo*. 5% Citric acid was added and the mixture extracted with chloroform three times. The combined organic phase was washed with brine, dried (magnesium sulfate) and the solvent removed *in vacuo* to give the titled carboxylic acid (245 mg, 86%) (for spectral data see Table VII).

30

- 39 -

EXAMPLE 25

4-p-toluy1-2-(2'-(5-(N-morpholinocarbonyl)pentanoyl)aminosulfonyl)
biphen-4-yl)methyl-phthalazin-1-(2H)-one.

- 5 Carbonyl diimidazole (32 mg, 0.2 mmol) was added to a stirred solution of the carboxylic acid (Example 24) (40 mg, 0.066 mmol) in THF (3 mL) under nitrogen at room temperature. The solution was heated at 65 °C for 3 hr. After cooling to room temperature, morpholine (9 µL, 0.1 mmol) was added and the mixture
10 heated at 50 °C for 18 hr. The solution was concentrated to dryness *in vacuo*. 5% Citric acid solution was added and the mixture extracted with ethyl acetate three times. The combined organic phase was washed with brine, dried (magnesium sulfate) and the solvent removed *in vacuo*. The residue was pre-absorbed on silica gel and chromatographed
15 (0 - 5% methanol/methylene chloride) to give the titled morpholino amide compound (15 mg, 33%) (for spectral data see Table VII).

EXAMPLE 26

- 20 4-p-toluy1-2-(2'-(5-(N,N-dimethylcarboxamido)pentanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

- The titled dimethyl amide was synthesized from the carboxylic acid (Example 24) and dimethylamine using the procedure outlined for Example 25. Chromatography (0 - 3%
25 methanol/methylene chloride) afforded the dimethyl amide (15.5 mg, 37%) (for spectral data see Table VII).

EXAMPLE 27

- 30 4-p-toluy1-2-(2'-(6-(N-acetamido)hexanoyl)aminosulfonyl)-biphen-4-yl)methyl-phthalazin-1-(2H)-one.

Acetic anhydride (0.5 mL) followed by dimethylamino-pyridine (3 mg) was added to the amine hydrochloride (obtained from Example 15) (30 mg, 0.048 mmol) under nitrogen at room

- 40 -

temperature. The solution was stirred at room temperature for 18 hr. then water added. The solid which precipitated was isolated by filtration and dried *in vacuo*. Recrystallization (ethyl acetate/diethyl ether) gave the titled acetamide (14.5 mg, 48%) (for spectral data see Table VII).

5

EXAMPLE 28

4-p-toluy1-2-(2'-(6-(N,N-dimethylcarbamoyl)hexanoyl)aminosulfonyl) biphen-4-yl)methyl-phthalazin-1-(2H)-one.

DBU (66 μ L, 0.441 mmol) was added to the amine
10 hydrochloride (Example 15) (80 mg, 0.127 mmol) in THF (3 mL) under nitrogen at 0 °C. Dimethylcarbamyl chloride (17.5 μ L, 0.190 mmol) was added and stirring continued at 0 °C for 3 hr. 5% Citric acid solution was added and the mixture extracted with ethyl acetate four times. The combined organic phase was washed with water, brine, dried
15 (magnesium sulfate) and the solvent removed *in vacuo*. The residue was chromatographed (4% methanol/methylene chloride) to give the titled dimethyl urea (56 mg, 66%) (for spectral data see Table VII).

EXAMPLE 29

20

4-p-toluy1-2-(2'-(6-(N-iso-propylsulfonamido)hexanoyl)aminosulfonyl) biphen-4-yl)methyl-phthalazin-1-(2H)-one.

DBU (35 μ L, 0.24 mmol) was added to the amine
hydrochloride (Example 15) (50 mg, 0.08 mmol) in THF (3 mL) under
25 nitrogen at 0°C. *Iso*-propylsulfonoyl chloride (13 μ L, 0.035 mmol) was added and stirring continued at 0°C for 3 hr. The solution was concentrated *in vacuo* then 5% citric acid solution added. The mixture was extracted with ethyl acetate four times. The combined organic
phase was washed with brine, dried (magnesium sulfate) and the solvent
30 removed *in vacuo*. The residue was pre-absorbed on silica gel and chromatographed (0 - 10% methanol/methylene chloride) to give the *iso*-propylsulfonamide (28 mg, 50%) (for spectral data see Table VIII).

- 41 -

EXAMPLE 30

4-p-toluy1-2-(2'-(4-aminobutanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

- 5 A saturated solution of hydrogen chloride in ethyl acetate (1 mL) was added to the t-Boc-compound (obtained from Example 21) (61 mg, 0.091 mmol) and the mixture stirred at room temperature for 1 hr. The volatile components of the mixture were removed *in vacuo* and the residue recrystallized (ethyl acetate/diethyl ether) to give the titled
10 amine as the hydrochloride salt (38 mg, 74%) (for spectral data see Table VIII).

EXAMPLE 31

- 15 4-p-toluy1-2-(2'-(4-(N,N-dimethylcarbamoyl)butanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

- DBU (28 μ L, 0.25 mmol) was added to the amine hydrochloride (Example 30) (45 mg, 0.07 mmol) in THF (1.5 mL) under nitrogen at 0 °C. Dimethylcarbamyl chloride (10 μ L, 0.11 mmol)
20 was added and stirring continued at 0 °C for 5 hr. The solution was concentrated *in vacuo* then 5% citric acid solution added. The mixture was extracted with ethyl acetate four times. The combined organic phase was washed with brine, dried (magnesium sulfate) and the solvent removed *in vacuo*. The residue was pre-absorbed on silica gel and
25 chromatographed (0 - 10% methanol/ methylene chloride) to give the titled dimethyl urea (16 mg, 36%) (for spectral data see Table VIII).

EXAMPLE 32

- 30 4-p-toluy1-2-(2'-(5-(N-pyrrolidinocarbonyl)pentanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

The titled pyrrolidine amide was synthesized from the carboxylic acid (Example 24) and pyrrolidine using the procedure outlined for Example 25. The crude product was pre-absorbed on silica

- 42 -

gel and chromatographed (0 - 10% methanol/methylene chloride) to give the pyrrolidine amide (29 mg, 67%) (for spectral data see Table VIII).

EXAMPLE 33

5 4-p-toluy1-2-(2'-(3-(N,N-dimethylcarboxamido)propylaminocarbonyl)-aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one.

DBU (29 μ L, 0.20 mmol) followed by carbonyl diimidazole (48.8 mg, 0.30 mmol) was added to 3-(dimethylamido)butyl
10 amine hydrochloride (50 mg, 0.30 mmol) in THF (3 mL) under nitrogen at room temperature. After stirring at room temperature for 2.5 hr., a solution of the sulfonamide (Example 2) (48 mg, 0.10 mmol) and DBU (45 μ L, 0.30 mmol) was added and the mixture stirred at room temperature for a further 18 hr. The solution was concentrated *in*
15 *vacuo* then 5% citric acid solution added. The mixture was extracted with ethyl acetate four times. The combined organic phase was washed with brine, dried (magnesium sulfate) and the solvent removed *in vacuo*. Recrystallization (ethyl acetate/diethyl ether) gave the titled sulfonyl urea (18 mg, 28%) (for spectral data see Table VIII).

20

25

30

- 43 -

EXAMPLE 34

4-p-toluy1-2-(2'-(hexylaminocarbonylamino sulfonyl)biphen-4-yl)methylphthalazin-1-(2H)-one

DBU (37 μ L, 0.25 mmol) was added to a stirred solution of
5 the free sulfonamide (Example 2) (48 mg, 0.10 mmol) in THF (3 mL)
under nitrogen at room temperature. After stirring for 0.5 hr. hexyl
isocyanate (27 μ L, 0.25 mmol) was added and the mixture stirred for
18 hr. The solvent was removed *in vacuo* then 5% citric acid solution
10 added. The mixture was extracted with ethyl acetate three times. The
combined organic phase was washed with brine, dried (magnesium
sulfate) and the solvent removed *in vacuo*. The residue was pre-
absorbed on silica gel and chromatographed (5% methanol/methylene
chloride, 0.5% ammonia) to give the titled sulfonyl urea that was
15 recrystallized from ethyl acetate/hexane (9.1 mg, 15%) (for spectral
data see Table IX).

EXAMPLES 35 - 37

20 Examples 35-37 were prepared using the procedure
outlined for Example 34 (See Table IX).


EXAMPLES 38 - 47

25 Examples 38-47 were prepared using appropriate
procedures as outlined for Examples 1-33 (See Table IX).

30

- 44 -

Table VI



Exam ples.	R ⁹ (NMR solvent)			NMR		MS (FAB)
		Aromatic Protons	Benzyl Protons (s, 2H)	Tolyl Methyl (s, 3H)	R Group Protons	
20	(CH ₂) ₅ NMe ₂ (CD ₃ OD/CDCl ₃)	8.45 (m, 1H) 8.15 (d, 1H) 7.83 (m, 3H) 7.58-7.18 (m, 11H)	5.50	2.44	3.34 (m, 2H) 2.66 (s, 6H) 1.84 (t, 2H) 1.51 (t, 2H) 1.24 (m, 4H)	623.4 (M+H)
21	(CH ₂) ₃ NHBoc (CDCl ₃)	8.48 (m, 1H) 8.23 (d, 1H) 7.78 (m, 3H) 7.62-7.25 (m, 11H)	5.52	2.44	2.95 (m, 2H) 1.82 (t, 2H) 1.51 (m, 2H) 1.41 (s, 9H)	669.5 (M+H)
22	(CH ₂) ₃ CONMe ₂ (CDCl ₃)	8.49 (m, 1H) 8.25 (d, 1H) 7.79 (m, 3H) 7.62-7.26 (m, 11H)	5.51	2.44	2.89 (s, 3H) 2.87 (s, 3H) 2.21 (t, 2H) 1.93 (t, 2H) 1.66 (m, 2H)	623.9 (M+H)

- 45 -

Table VII



Exam ples	R ⁹ (NMR solvent)			NMR		MS (FAB)
		Aromatic Protons	Benzyl Protons (s, 2H)	Tolyl Methyl (s, 3H)	R Group Protons	
23	(CH ₂) ₄ COOEt (CDCl ₃)	8.50 (m, 1H) 8.25 (d, 1H) 7.80 (m, 3H) 7.60-7.24 (m, 11H)	5.51	2.45	4.07 (q, 2H) 2.12 (t, 2H) 1.80 (t, 2H) 1.37 (m, 4H) 1.20 (t, 3H)	638.4 (M+H)
24	(CH ₂) ₄ COOH (CDCl ₃)	8.50 (m, 1H) 8.26 (m, 1H) 7.81 (m, 3H) 7.61-7.24 (m, 11H)	5.57	2.45	2.31 (t, 2H) 1.93 (t, 2H) 1.61 (m, 2H) 1.45 (m, 2H)	610.4 (M+H)
25	(CH ₂) ₄ CON  (CDCl ₃)	8.48 (m, 1H) 8.25 (d, 1H) 7.80 (m, 3H) 7.60-7.25 (m, 11H)	5.50	2.44	3.65 (m, 4H) 3.56 (m, 2H) 3.36 (m, 2H) 2.16 (t, 2H) 1.86 (t, 2H) 1.39 (m, 4H)	679.5 (M+H)
26	(CH ₂) ₄ CONMe ₂ (CDCl ₃)	8.50 (m, 1H) 8.25 (d, 1H) 7.81 (m, 3H) 7.62-7.24 (m, 11H)	5.50	2.44	2.91 (s, 3H) 2.89 (s, 3H) 2.16 (t, 2H) 1.87 (t, 2H) 1.40 (m, 4H)	637.0 (M+H)

Table VII (Continued)

Exam ples	R ⁹ (NMR solvent)			NMR		MS (FAB)
		Aromatic Protons	Benzyl Protons (s, 2H)	Tolyl Methyl (s, 3H)	R Group Protons	
27	(CH ₂) ₅ NHCOMe (CDCl ₃)	8.48 (m, 1H) 8.24 (d, 1H) 7.80 (m, 3H) 7.64-7.25 (m, 11H)	5.51	2.44	3.12 (m, 2H) 1.91 (s, 3H) 1.77 (t, 2H) 1.34 (m, 4H) 1.11 (m, 2H)	637 (M+H)
28	(CH ₂) ₅ NHCONMe ₂ (CD ₃ OD/CDCl ₃)	8.44 (m, 1H) 8.17 (d, 1H) 7.83 (m, 3H) 7.65 (m, 11H)	5.51	2.43	3.02 (m, 2H) 2.82 (s, 6H) 1.78 (t, 2H) 1.31 (m, 4H) 1.08 (m, 2H)	665.9 (M+1)

- 47 -

Table VIII

Exam ples	R ⁹ (NMR solvent)			NMR		MS (FAB)
		Aromatic Protons	Benzyl Protons (s, 2H)	Tolyl Methyl (s, 3H)	R Group Protons	
5 29	(CH ₂) ₅ NHSO ₂ iPr (CDCl ₃)	8.48 (m, 1H) 8.24 (d, 1H) 7.80 (m, 3H) 7.62-7.24 (m, 11H)	5.52	2.45	4.45 (m, 1H) 3.04 (m, 2H) 1.76 (t, 2H) 1.43 (m, 2H) 1.35 (m, 2H) 1.33 (d, 6H) 1.18 (m, 2H)	701 (M+H)
10 30	(CH ₂) ₃ NH ₂ .HCl (CD ₃ OD)	8.46 (m, 1H) 8.16 (d, 1H) 7.92-7.85 (m, 3H) 7.67-7.30 (m, 11H)	5.54	2.46	2.79 (t, 2H) 1.93 (t, 2H) 1.67 (m, 2H)	567.8 (M+H)
15 31	(CH ₂) ₃ NHCONMe ₂ (CDCl ₃)	8.47 (m, 1H) 8.25 (d, 1H) 7.77 (m, 3H) 7.57-7.26 (m, 11H)	5.54	2.44	3.05 (m, 2H) 2.80 (s, 6H) 1.85 (t, 2H) 1.53 (m, 2H)	638.2 (M+H)
20 32	(CH ₂) ₄ CON  (CDCl ₃)	8.48 (m, 1H) 8.25 (d, 1H) 7.76 (m, 3H) 7.57-7.36 (m, 11H)	5.50	2.44	3.40 (t, 2H) 3.31 (t, 2H) 2.13 (t, 2H) 1.89 (m, 4H) 1.86 (m, 2H) 1.39 (m, 4H)	663.2 (M+H)
25 33	NH(CH ₂) ₃ CONMe ₂ (CDCl ₃)	8.48 (m, 1H) 8.16 (d, 1H) 7.77 (m, 3H) 7.56-7.26 (m, 11H)	5.50	2.44	3.08 (m, 2H) 2.91 (s, 3H) 2.88 (s, 3H) 2.18 (t, 2H) 1.69 (m, 2H)	638.3 (M+H)
30						

- 48 -

Table IX

Examples	R ⁹	Nmr Spectrum	MS (FAB)
34	NH(CH ₂) ₅ CH ₃	X	581.8 (M+H)
35	NH(CH ₂) ₃ CH ₃	X	609.6 (M+H)
36	NH(CH ₂) ₃ Cl	X	601.8 (M+H)
37	NH(CH ₂) ₂ - 2-Thienyl	X	635.3 (M+H)
38	(CH ₂) ₂ CH- (C(O)OtBu)NHBoc	X	768.2 (M+H)
39	2-Thienyl	X	592.6 (M+H)
40	3-Furyl	X	576.8 (M+H)
41	(CH ₂) ₂ OCH ₃	X	568.8 (M+H)
42	2-Furyl	X	576.7 (M+H)
43	CH ₂ OCH ₂ CH ₃	X	568.8 (M+H)
44	(CH ₂) ₅ OH	X	596.9 (M+H)
45	(CH ₂) ₃ NHCOMe	X	609.6 (M+H)
46	(CH ₂) ₄ CONH ₂	X	609.5 (M+H)
47	(CH ₂) ₄ CONHMe	X	623.5 (M+H)

- 49 -

EXAMPLE 48

Step 1: 4-(Morpholinomethyl)phenyl-2-[(2'-t-butylamino-sulfonyl)biphen-4-yl]methyl-phthalazin-1-(2H)-one.

A mixture of 4-p-toluy1-2-[(2'-t-butylaminosulfonyl)-
5 biphen-4-yl]methyl-phthalazin-1-(2H)-one (0.27 g, 0.5 mMol), N-bromo-succinimide (0.09 g, 0.5 mMol) and azaisobutyro-nitrile (AIBN) (0.01g) was refluxed for 3h and then cooled down to room temperature. The mixture was filtered and the filtrate concentrated *in vacuo* to give a foam (0.3g). The foam was dissolved in methylene chloride (5 mL) and
10 cooled in an ice-bath. Morpholine (1 mL) was then added, and the mixture was stirred at room temperature for 15 h. The reaction mixture was concentrated *in vacuo* and the residue obtained was purified by flash chromatography [silica-gel using initially ethyl acetate-hexane (1:2) and then ethyl acetate-hexane (2:1)] to give the titled product as
15 white solid (0.16g).
¹H-NMR(CDCl₃): δ 8.52 (m, 1H), 8.15 (d, 1H), 7.79 (m, 3H), 7.36-7.65 (m, 10 H), 7.23 (m, 1H), 5.52 (s, 2H), 3.75 (t, 4H), 3.60(s, 2H), 3.51 (s, 1H), 2.52 (t, 4H), 0.91 (s, 9H).
FAB-MS: (m/e) 609 (M+H).

20

Step 2: 4-(Morpholinomethyl)phenyl-2-[(2'-(6-(N-t-butyloxy carbonylamino)hexanoyl)aminosulfonyl)-biphen-4-yl]methyl-phthalazin-1-(2H)-one.

4-(Morpholinomethyl)phenyl-2-[(2'-aminosulfonyl)-
25 biphen-4-yl]methyl-phthalazin-1-(2H)-one [prepared from 4-(Morpholinomethyl)phenyl-2-[(2'-t-butylaminosulfonyl)biphen-4-yl]methyl-phthalazin-1-(2H)-one according to the procedure described in Example 2; Step 2] (0.1g, 0.18 mMol) was reacted in THF (3 mL) with the acyl-imidazole [prepared from N-t-Boc-amino hexanoic acid
30 (0.083 g, 0.36 mMol) and N,N-carbonyldiimidazole (0.06 g, 0.36 mMol)] and DBU (0.053 mL), according to the procedure described in Example 10. The titled compound was obtained as a foam (0.12g), after purification of the crude product by flash chromatography (silica-gel, chloroform-methanol-NH₄OH-100:10:1).

- 50 -

¹H-NMR (CDCl₃): δ 8.50 (m, 1H), 8.22 (d, 1H), 7.78 (m, 3H), 7.15-7.60 (m, 11 H), 5.52 (s, 2H), 3.75 (t, 4H), 3.60 (s, 2H), 3.0 (m, 2H), 2.52 (t, 4H), 1.84 (t, 2H), 1.44 (s, 9H), 1.1-1.4 (m, 6H).
FAB-MS: (m/e) 780 (M+H).

- 5 Step 3: 4-(Morpholinomethyl)phenyl-2-[(2'-(6-aminohexanoyl)-aminosulfonyl)-biphen-4-yl]methyl-phthalazin-1-(2H)-one.
4-(Morpholinomethyl)phenyl-2-[(2'-(6-(N-t-butyloxy-carbonylamino)hexanoyl)aminosulfonyl)-biphen-4-yl]-methyl-phthalazin-1-(2H)-one, obtained in step 2, (0.10 g) was dissolved in a
10 mixture of methylene chloride (1 mL) and anhydrous trifluoroacetic acid (1 mL). The mixture was stirred at room temperature for 1h then concentrated in vacuo to dryness. Dry ether was added and the solid obtained was filtered and dried to give the titled compound as the ditrifluoroacetic acid salt (0.08 g).
15 ¹H-NMR (CD₃OD): δ 8.50 (m, 1H), 8.22 (d, 1H), 7.78 (m, 3H), 7.15-7.60 (m, 11 H), 5.52 (s, 2H), 3.75 (t, 4H), 3.60 (s, 2H), 3.0 (m, 2H), 2.52 (t, 4H), 1.84 (t, 2H), 1.2-1.4 (m, 6H).
FAB-MS: (m/e) 680 (M+H)

20

EXAMPLE 49

Typical Pharmaceutical Compositions Containing a Compound of the Invention [e.g. 4-p-toluy-2-(2'-(5-(N,N-dimethyl-carboxamido)-pentanoyl)aminosulfonyl)biphen-4-yl)methyl-phthalazin-1-(2H)-one
25 (Example 26)].

A: Dry Filled Capsules Containing 50 mg of Active Ingredient
Per Capsule

<u>Ingredient</u>	<u>Amount per capsule (mg)</u>
Title compound of Example 26	50
Lactose	149
Magnesium stearate	1
Capsule (size No. 1)	200

- 51 -

The title compound of Example 26 can be reduced to a No. 60 powder and the lactose and magnesium stearate can then be passed through a No. 60 blotting cloth onto the powder. The combined ingredients can then be mixed for about 10 minutes and filled into a No. 1 dry gelatin capsule.

B: Tablet

A typical tablet would contain the title compound of Example 26 (25 mg), pregelatinized starch USP (82 mg), microcrystalline cellulose (82 mg) and magnesium stearate (1 mg).

C: Suppository

Typical suppository formulations for rectal administration can contain the title compound of Example 26 (1-25 mg), butylated hydroxyanisole (0.08-1.0 mg), disodium calcium edetate (0.25-0.5 mg), and polyethylene glycol (775-1600 mg). Other suppository formulations can be made by substituting, for example, butylated hydroxytoluene (0.04-0.08 mg) for the disodium calcium edetate and a hydrogenated vegetable oil (675-1400 mg) such as Suppocire L, Wecobee FS, Wecobee M, Witepsols, and the like, for the polyethylene glycol.

D: Injection


A typical injectable formulation would contain the title compound of Example 26 (5.42 mg), sodium phosphate dibasic anhydrous (11.4 mg) benzyl alcohol (0.01 ml) and water for injection (1.0 ml).

30

- 52 -

WHAT IS CLAIMED IS:

1. A compound of structural formula I:



20 or a pharmaceutically acceptable thereof,
wherein:

R^1 is:

- 25
- (a) $-NHSO_2NHCOR^9$,
 - (b) $-NHCONHSO_2R^9$,
 - (c) $-SO_2NHR^9$,
 - (d) $-SO_2NHCOR^9$,
 - (e) $-SO_2NHCONR^7R^9$, or
 - (f) $-SO_2NHCOOR^9$;
- 30

R^{2a} and R^{2b} are each independently:

- (a) H,
- (b) Cl, Br, I, F,
- (c) CF_3 ,

- 53 -

- (d) C₁-C₆-alkyl,
(e) C₁-C₆-alkoxy,
(f) C₁-C₆-alkyl-S-,
(g) C₂-C₆-alkenyl,
(h) C₂-C₆-alkynyl,
5 (i) C₃-C₇-cycloalkyl,
(j) aryl, as defined in R⁴ below, or
(k) aryl-C₁-C₆-alkyl;

R^{3a} is:

- 10 (a) H,
(b) Cl, Br, I, F,
(c) C₁-C₆-alkyl,
(d) C₁-C₆-alkoxy, or
15 (e) C₁-C₆-alkoxyalkyl;

R^{3b} is:

- (a) H,
(b) Cl, Br, I, F,
(c) C₁-C₆-alkyl,
20 (d) C₃-C₇-cycloalkyl,
(e) C₁-C₆-alkoxy,
(f) CF₃,
(g) C₂-C₆-alkenyl, or
25 (h) C₂-C₆-alkynyl;

R⁴ is:

- (a) H,
(b) C₁-C₆-alkyl optionally substituted with a substituent
30 selected from the group consisting of: C₁-C₄-alkoxy, aryl,
heteroaryl, -CON(R¹⁰)₂, -N(R¹⁰)₂, -O-COR¹⁰ and
-COR¹⁰ or
(c) aryl, wherein aryl is phenyl or naphthyl, either
unsubstituted or substituted with one or two substituents
selected from the group consisting of Cl, F, Br, I, N(R⁷)₂,

- 54 -

NR⁷COOR⁹, NR⁷CONR⁷R⁹, CO₂R⁷, CONR⁷R⁹, C₁-C₄-alkyl, -(C₁-C₄)alkyl-Y, NO₂, OH, CF₃, C₁-C₄-alkoxy, -S(O)_x-(C₁-C₄)alkyl, and -(C₁-C₄)alkyl-N-(CH₂-CH₂)₂Q,

- (d) heteroaryl, wherein heteroaryl is defined as thiazole, imidazole, pyrazole, oxazole, isoxazole pyridine, thiazine, quinoline, isoquinoline, phthalazine, quinazoline, pyridazine, pyrazine, or pyrimidine and wherein the heteroaryl is unsubstituted or substituted with one or two substituents selected from the group consisting of: -OH, -SH, -C₁-C₄-alkyl, -C₁-C₄-alkoxy, -CF₃, Cl, Br, F, I, -NO₂, -CO₂H, -CO₂-(C₁-C₄-alkyl), -NH₂, -NH(C₁-C₄-alkyl) and -N(C₁-C₄-alkyl)₂, NR⁷COOR⁹ and NR⁷CONR⁷R⁹,

(e) C₃-C₇-cycloalkyl, or

(f) -COaryl;

Q is: a single bond, -CH₂-, O, NR⁷, or S(O)_x;

Y is: COOR⁹, CN, NR⁷COOR⁹ or CONR⁷R⁹;

R⁵ and R⁶ are independently:

- (a) H,
 (b) C₁-C₆-alkyl, unsubstituted or substituted with a substituent selected from the group consisting of: -OH, -guanidino, C₁-C₄-alkoxy, -N(R⁷)₂, COOR⁷, -CON(R⁷)₂, -O-COR⁷, -aryl, -heteroaryl, -S(O)_x-R⁹, -tetrazol-5-yl, -CONHSO₂R⁹, -SO₂NH-heteroaryl, -SO₂NHCOR⁹, -PO(OR⁷)₂, -PO(OR⁸)R⁷, -SO₂NH-CN, -NR⁸COOR⁹, morpholino, N-(C₁-C₆-alkyl)-piperazine, and -COR⁷,
 (c) -CO-aryl,
 (d) -C₃-C₇-cycloalkyl,
 (e) Cl, Br, I, F,
 (f) -OH,
 (g) -OR⁹,

- 55 -

- (h) $-C_1-C_4$ -perfluoroalkyl,
 (i) $-S(O)_x-R^9$,
 (j) $-COOR^7$,
 (k) $-SO_3H$,
 5 (l) $-NR^7R^9$,
 (m) $-NR^7COR^9$,
 (n) $-NR^7COOR^9$,
 (o) $-SO_2NR^7R^8$,
 (p) $-NO_2$,
 10 (q) $-NR^7SO_2R^9$,
 (r) $-NR^7CONR^7R^9$,
 (s) $-OCONR^9R^7$,
 (t) $-aryl$,
 (u) $-NHSO_2CF_3$,
 15 (v) $-SO_2NH$ -heteroaryl,
 (w) $-SO_2NHCOR^9$,
 (x) $-CONHSO_2R^9$,
 (y) $-PO(OR^7)_2$,
 (z) $-PO(OR^8)R^7$,
 20 (aa) $-tetrazol-5-yl$,
 (bb) $-CONH(tetrazol-5-yl)$,
 (cc) $-COR^7$,
 (dd) $-SO_2NHCN$,
 (ee) $-CO$ -heteroaryl,
 25 (ff) $-NR^7SO_2NR^9R^7$,
 (gg) $-N[CH_2CH_2]_2NR^{11}$,
 (hh) $-N[CH_2CH_2]_2O$, or
 (ii) $-heteroaryl$ as defined above;
- 30 x is: 0, 1, or 2,
 R^7 is: H, C_1-C_5 -alkyl, aryl, or $-CH_2$ -aryl;

- 56 -

R⁸ is: H, or C₁-C₄-alkyl;

R⁹ is:

- 5 (a) aryl,
(b) heteroaryl,
(c) C₃-C₇-cycloalkyl,
(d) C₁-C₈-alkyl, wherein alkyl is unsubstituted or substituted
with one or two substituents selected from the group
consisting of: aryl, heteroaryl, -OH, -SH, C₁-C₄-alkyl,
-O(C₁-C₄-alkyl), -S(C₁-C₄-alkyl), -CF₃, Cl, Br, F, I,
10 -NO₂, -CO₂H, -CO₂-C₁-C₄-alkyl, -NH₂, -NR⁷CO₂R¹⁰,
-NH(C₁-C₄-alkyl), -N(C₁-C₄-alkyl)₂, -PO₃H₂,
-PO(OH)(O-C₁-C₄-alkyl), -PO(OR⁸)R⁷, -NR⁷COR¹⁰,
-CONR⁷R¹⁰, -OCONR⁷R¹⁰, -SO₂NR⁷R¹⁰, -NR⁷SO₂R¹⁰,
15 -N(CH₂-CH₂)₂Q and -CON(CH₂-CH₂)₂Q or
(e) perfluoro-C₁-C₄-alkyl;

R¹⁰ is:

- 20 (a) aryl,
(b) heteroaryl,
(c) C₁-C₆-alkyl, wherein alkyl is unsubstituted or substituted
with a substituent selected from the group consisting of:
aryl, heteroaryl, -OH, -NH₂, -NH(C₁-C₄-alkyl), -N(C₁-
C₄-alkyl)₂, -CO₂R⁷, Cl, Br, F, I, and -CF₃, or
25 (d) perfluoro-C₁-C₄-alkyl;

R¹¹ is: C₁-C₆-alkyl, C₃-C₇-cycloalkyl, -CONR⁷R⁸,
heteroaryl, phenyl, -CO-C₃-C₇-cycloalkyl,
or -CO-C₁-C₆-alkyl; and

30

r is: 1 or 2.

- 57 -

2. The method of claim 1, wherein:

R¹ is:

- (a) -NHSO₂NHCOR⁹, or
- (b) -NHCONHSO₂R⁹;

5

R^{2a} is: H;R^{2b} is: H, F, Cl, CF₃, C₁-C₆-alkyl, C₂-C₄-alkenyl, or
C₂-C₄-alkynyl, aryl or aryl-C₁-C₆-alkyl;

10

R^{3a} is: H;R^{3b} is: H, F, Cl, CF₃, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-
alkynyl, or C₅-C₆-cycloalkyl;

15

R⁵ and R⁶ are each independently:

- (a) H,
- (b) C₁-C₆-alkyl unsubstituted or substituted with COOR⁷,
OCOR⁷, OH, or aryl,
- (c) -OH,
- (d) -NO₂,
- (e) -NHCOR⁹,
- (f) -C₁-C₄-alkoxy,
- (g) -NHCO₂R⁹,
- (h) -NR⁷R⁹,
- (i) -Cl, F, Br,
- (j) -CF₃,
- (k) -CO₂R⁷,
- (l) -CO-aryl,
- (m) -S(O)_x-C₁-C₄-alkyl,
- (n) -SO₂-NH-C₁-C₄-alkyl,
- (o) -SO₂-NH-aryl,
- (p) -NHSO₂CH₃,

20

25

30

- 58 -

- (q) -aryl,
- (r) -NHCONR⁷R⁹,
- (s) -N[CH₂CH₂]₂NR¹¹, or
- (t) -N[CH₂CH]₂O;

5 r is one.

3. The method of claim 2, wherein:

10 R¹ is:

- (a) -NHSO₂NHCOR⁹, or
- (b) -NHCONHSO₂R⁹;

15 R⁴ is: (C₁-C₆)-alkyl, aryl, aryl-(C₁-C₆)-alkyl, or
 heteroaryl as defined before; and

 R⁵ and R⁶ are each independently:

 H, -C₁-C₄-alkyl, -aryl, -NO₂, -NR⁷R⁹, -NHCOOR⁹,
20 -Cl, -CH₂COOH, -S(O)_x-C₁-C₄-alkyl, NHCONR⁷R⁹,
 NHCOR⁹, CO₂R⁹, -F, N[CH₂CH₂]₂NR¹¹, or
 N[CH₂CH₂]₂O.

25 4. The method of claim 1, wherein:

 R¹ is:

- (a) -SO₂NHR⁹,
- (b) -SO₂NHCOR⁹,
- 30 (c) -SO₂NHCONR⁷R⁹, or
- (d) -SO₂NHCOOR⁹;

 R^{2a} is: H;

- 59 -

R^{2b} is: H, F, Cl, CF₃, C₁-C₆-alkyl, C₂-C₄-alkenyl, or
C₂-C₄-alkynyl, aryl or aryl-C₁-C₆-alkyl;

R^{3a} is: H;

R^{3b} is: H, F, Cl, CF₃, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-
alkynyl, or C₅-C₆-cycloalkyl;

R⁵ and R⁶ are independently:

- (a) H,
- (b) C₁-C₆-alkyl, unsubstituted or substituted with COOR⁷,
OCOR⁷, OH, or aryl,
- (c) -OH,
- (d) -NO₂,
- (e) -NHCOR⁹,
- (f) -C₁-C₄-alkoxy,
- (g) -NHCO₂R⁹,
- (h) -NR⁷R⁹,
- (i) -Cl, F, Br,
- (j) -CF₃,
- (k) -CO₂R⁷,
- (l) -CO-aryl,
- (m) -S(O)_x-C₁-C₄-alkyl,
- (n) -SO₂-NH-C₁-C₄-alkyl,
- (o) -SO₂-NH-aryl,
- (p) -NHSO₂CH₃,
- (q) -aryl,
- (r) -NHCONR⁷R⁹,
- (s) -N[CH₂CH₂]₂NR¹¹, or
- (t) -N[CH₂CH₂]₂O; and

r is one.

- 60 -

5. The method of claim 4, wherein:

 R^1 is:

- 5 (a) $-\text{SO}_2\text{NHR}^9$,
(b) $-\text{SO}_2\text{NHCOR}^9$,
(c) $-\text{SO}_2\text{NHCONR}^7\text{R}^9$, or
(d) $-\text{SO}_2\text{NHCOOR}^9$;

 R^4 is: $(\text{C}_1\text{-C}_6)\text{alkyl}$, aryl, aryl- $(\text{C}_1\text{-C}_6)\text{alkyl}$, or heteroaryl; and

10

 R^5 and R^6 are each independently:

- 15 H, $-\text{C}_1\text{-C}_4\text{-alkyl}$, -aryl, $-\text{NO}_2$, $-\text{NR}^7\text{R}^9$, $-\text{NHCOOR}^9$,
Cl, $-\text{CH}_2\text{COOH}$, $-\text{S}(\text{O})_x\text{-C}_1\text{-C}_4\text{-alkyl}$, $\text{NHCONR}^7\text{R}^9$,
 NHCOR^9 , CO_2R^9 , -F, $\text{N}[\text{CH}_2\text{CH}_2]_2\text{NR}^{11}$, or
20 $\text{N}[\text{CH}_2\text{CH}_2]_2\text{O}$.


25

30

30

- 61 -

6. The method of claim 5, wherein the structural formula is:



and wherein the substituents are as defined in Table 1 below:

TABLE I

<u>R⁴</u>	<u>R⁵</u>	<u>R⁶</u>	<u>R⁹</u>
H	H	H	-(CH ₂) ₅ NHBoc
H	H	H	-(CH ₂) ₅ NH ₂
Methyl	H	H	-(CH ₂) ₅ NHBoc
Methyl	H	H	-(CH ₂) ₅ NH ₂
n-Propyl	H	i-propyl	-(CH ₂) ₅ NHBoc
n-Propyl	H	H	-(CH ₂) ₅ NHBoc
n-Propyl	H	H	-(CH ₂) ₅ NH ₂
i-Propyl	H	H	-cyclopropyl
i-Propyl	H	H	-(CH ₂) ₄ NHBoc
i-Propyl	H	H	-(CH ₂) ₄ NH ₂
Phenyl	H	H	-cyclopropyl
Phenyl	H	H	-(CH ₂) ₅ NHBoc
Phenyl	H	H	-(CH ₂) ₅ NH ₂
Phenyl	methyl	H	-(CH ₂) ₅ NHBoc

- 62 -

	R⁴	R⁵	R⁶	R⁹
	Phenyl	methyl	H	-(CH ₂) ₅ NH ₂
	p-Toluy	H	H	-(CH ₂) ₅ NHCOCH ₃
	p-Toluy	H	methyl	-(CH ₂) ₅ NH ₂
5	p-Toluy	H	methyl	-(CH ₂) ₅ NHBoc
	4-Cl-Phenyl	H	H	-(CH ₂) ₅ NHBoc
	4-Cl-Phenyl	H	H	-(CH ₂) ₅ NH ₂
	4-Cl-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	4-Cl-Phenyl	H	methyl	-(CH ₂) ₅ NHBoc
10	4-Br-Phenyl	H	H	-(CH ₂) ₅ NHBoc
	4-Br-Phenyl	H	H	-(CH ₂) ₅ NH ₂
	4-F-Phenyl	H	H	-(CH ₂) ₅ NHBoc
	4-F-Phenyl	H	H	-(CH ₂) ₅ NH ₂
	4-OMe-Phenyl	H	H	-(CH ₂) ₅ NHBoc
15	4-OMe-Phenyl	H	H	-(CH ₂) ₅ NH ₂
	p-Toluy	H	H	-(CH ₂) ₅ NHBoc
	p-Toluy	H	H	-(CH ₂) ₅ NH ₂
	p-Toluy	H	H	-(CH ₂) ₆ NHBoc
	p-Toluy	H	H	-(CH ₂) ₆ NH ₂
20	p-Toluy	H	H	-(CH ₂) ₃ NHBoc
	p-Toluy	H	H	-(CH ₂) ₃ NH ₂
	p-Toluy	H	H	-(CH ₂) ₄ NHBoc
	p-Toluy	H	H	-(CH ₂) ₄ NH ₂
	p-Toluy	H	H	-(CH ₂) ₆ OH
25	p-Toluy	H	H	-(CH ₂) ₅ COOC ₂ H ₅
	p-Toluy	H	H	-(CH ₂) ₄ COOH
	p-Toluy	methyl	H	-(CH ₂) ₅ COOC ₂ H ₅
	p-Toluy	H	H	-(CH ₂) ₆ CH ₃
	p-Toluy	H	H	-(CH ₂) ₅ CONHCH ₃
30	p-Toluy	H	H	-(CH ₂) ₅ CON(CH ₃) ₂
	p-Toluy	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	p-Toluy	H	H	-(CH ₂) ₄ CON(CH ₂) ₄

- 63 -

	R⁴	R⁵	R⁶	R²
	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂) ₅
	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂ CH ₂) ₂ O
	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂ CH ₂) ₂ NH
	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂ CH ₂) ₂ NAc
5	p-Toluyyl	H	H	-(CH ₂) ₄ CON(CH ₂ CH ₂) ₂ NCH ₃
	p-Toluyyl	H	H	-(CH ₂) ₆ CON(CH ₃) ₂
	p-Toluyyl	H	H	-(CH ₂) ₂ CH(NHBoc)COOtBu
	p-Toluyyl	H	H	-2-thienyl
	p-Toluyyl	H	H	-3-furyl
10	p-Toluyyl	H	H	-2-furyl
	p-Toluyyl	H	H	-(CH ₂) ₂ OCH ₃
	p-Toluyyl	H	H	-NH(CH ₂) ₃ CH ₃
	p-Toluyyl	H	H	-NH(CH ₂) ₅ CH ₃
	p-Toluyyl	H	H	-NH(CH ₂) ₃ Cl
15	p-Toluyyl	H	H	-NH(CH ₂) ₂ -2-thienyl
	p-Toluyyl	H	H	-CH ₂ OCH ₂ CH ₃
	p-Toluyyl	H	H	-(CH ₂) ₅ OH
	p-Toluyyl	H	H	-NH(CH ₂) ₅ CH ₃
	p-Toluyyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
20	p-Toluyyl	H	H	-(CH ₂) ₅ NHCH ₃
	1-Naphthyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
	1-Naphthyl	H	H	-(CH ₂) ₅ CON(CH ₃) ₂
	1-Naphthyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	1-Naphthyl	H	H	-(CH ₂) ₅ NHBoc
25	1-Naphthyl	H	H	-(CH ₂) ₅ NH ₂
	4-OMe-Phenyl	H	H	-(CH ₂) ₅ CON(CH ₃) ₂
	4-OMe-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	2-Naphthyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
	2-Naphthyl	H	H	-(CH ₂) ₅ CON(CH ₃) ₂
30	2-Naphthyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	2-Naphthyl	H	H	-(CH ₂) ₅ NHBoc
	2-Naphthyl	H	H	-(CH ₂) ₅ NH ₂

- 64 -

	R⁴	R⁵	R⁶	R²
	Pentamethylphenyl	H	H	-(CH ₂) ₅ NH ₂
	Pentamethylphenyl	H	H	-(CH ₂) ₅ NHBoc
	Pentamethylphenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
5	2-pyridyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	4-pyridyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	2-Thienyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	2-pyridyl	H	H	-(CH ₂) ₅ NHBoc
	2-pyridyl	H	H	-(CH ₂) ₅ NH ₂
10	2-pyridyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
	4-pyridyl	H	H	-(CH ₂) ₅ NHBoc
	4-pyridyl	H	H	-(CH ₂) ₅ NH ₂
	4-pyridyl	H	H	-(CH ₂) ₅ N(CH ₃) ₂
	4-pyridyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
15	2-Thienyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	4-(N-Morpholinomethyl)- phenyl	H	H	-(CH ₂) ₅ NHBoc
	4-(N-Morpholinomethyl)- phenyl	H	H	-(CH ₂) ₅ NH ₂
20	4-(N-Pyrrolidinomethyl)- phenyl	H	H	-(CH ₂) ₅ NHBoc
	4-(N-Pyrrolidinomethyl)- phenyl	H	H	-(CH ₂) ₅ NH ₂
25	4-(N-Pyrrolidinomethyl)- phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	4-(N-Morpholinomethyl)- phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
	p-ToluyI	H	H	-(CH ₂) ₃ CON(CH ₃) ₂
	p-ToluyI	H	H	-(CH ₂) ₅ NHCON(CH ₃) ₂
30	p-ToluyI	H	H	-(CH ₂) ₅ NHSO ₂ iPr
	p-ToluyI	H	H	-(CH ₂) ₃ NHCON(CH ₃) ₂
	p-ToluyI	H	H	-NH(CH ₂) ₃ CON(CH ₃) ₂
	p-ToluyI	H	H	-(CH ₂) ₃ NHCOCH ₃
	p-ToluyI	H	H	-(CH ₂) ₄ CONH ₂

- 65 -

p-ToluyI	H	H	-(CH ₂) ₄ CONHCH ₃
4-Cl-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
4-F-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂
2-CH ₃ CONH-Phenyl	H	H	-(CH ₂) ₄ CON(CH ₃) ₂

5 7. A method of treating a condition in a mammal, the treatment of which is effected or facilitated by a decrease in neurotensin mediated actions, comprising the administration of a compound of structural formula I as recited in Claim 1, in an amount that is effective for antagonizing the effect of neurotensin.

10

8. The method of claim 7, wherein the condition is selected from the group consisting of : psychoses, depression, Alzheimer's disease, anxiety, gastroesophageal reflux disorder (GERD), irritable bowel syndrome, diarrhea, cholic, ulcer, GI tumor, dyspepsia, 15 pancreatitis or esophagitis.

9. The method of claim 8, wherein the condition is psychoses.

20

10. The method of treating a condition through neurotensin receptor blockade by administering to a mammal in need of such treatment a therapeutically effective amount of a compound of structural formula I as defined in claim 1.

25

30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/10386

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ON LINE STRUCTURE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,393,062 (BRITAIN ET AL) 12 JULY 1983.	1-10

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

22 DECEMBER 1993

Date of mailing of the international search report

9.4 FEB 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

EMILY BERNHARDT TCE

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/10386

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (5):

C07D 237/32, 401/04, 401/06, 403/04, 403/06, 403/10, 409/04 409/06, 413/04, 413/06, 413/10, 417/04, 417/06;
A61K 31/50, 31/535, 31/54.

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

514/80, 222.2, 226.8, 228.2, 234.5, 248; 544/3, 55, 58.6, 62, 119, 232, 237.

B. FIELDS SEARCHED
Minimum documentation searched
Classification System: U.S.

514/80, 222.2, 226.8, 228.2, 234.5, 248; 544/3, 55, 58.6, 62, 119, 232, 237.

11.11.11

11.11.11

11.11.11